Journals / MN Kardiyoloji / 2000 / Cilt: 7 - Sayı: 6

Kombine hiperlipidemili hastalarda tekbaşına fluvastatin tedavisi

Pages
446–450
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The diet and exercise therapies on high-density lipoprotein cholesterol level were found to be effective as well as the drug therapies.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AIM: Combined hyperlipidemia is one of the risk factors for coronary heart disease.
📊
Key Findings & Data:Forty-four patients in first group received diet plus fluvastatin 40mg/day, thirty-five patients in second group received diet plus fluvastatin 80 mg/day and sixteen patients in third group received diet therapy.
💡
Conclusion & Impact:The diet and exercise therapies on high-density lipoprotein cholesterol level were found to be effective as well as the drug therapies.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Risk faktörleri · Koroner hastalık · Diyet

Abstract

AIM: Combined hyperlipidemia is one of the risk factors for coronary heart disease. We aimed that as a monotherapy, the effectiveness and safety of fluvastatin, which is HMG-CoA reductase inhibitor, on combined hyperlipidemia. METERIAL AND METHODS: Eighty-nine patients with combined hyperlipidemia were enrolled in this study. Forty-four patients in first group received diet plus fluvastatin 40mg/day, thirty-five patients in second group received diet plus fluvastatin 80 mg/day and sixteen patients in third group received diet therapy. Patients were followed up for a duration of 28 weeks. During follow up, all clinical comprehensive laboratory assessments were repeated for every 6 weeks. RESULTS: After 24 weeks of treatment the mean percent change from baseline was statistically significant for low density lipoprotein cholesterol ( %-32,l; p<0,001 in 40 mg/day , %-4,08; p<0,0001 in 80 mg/day), trygliceride (%-34,6; p<0,01 in 40 mg/day, %-46,5, p<0,0001 in 80 mg/day), apolipoprotein B (%-37,6; p<0,0001 in 80 mg/day) and high-density lipoprotein cholesterol (%+14,3; p<0,01 in 80 mg/day). The ratio of triglyceride/low density lipoprotein cholesterol was significantly higher in 80 mg/day group than diet group (1,14; p<0.05). CONCLUSION: Fluvastatin decreased the triglyceride, low density lipoprotein cholesterol and apolipoprotein B levels in serum. The diet and exercise therapies on high-density lipoprotein cholesterol level were found to be effective as well as the drug therapies.

Özet

AMAÇ: Lipit metabolizma bozukluklarından biri olan kombine hiperlipidemi koroner arter hastalığını arttıran önemli bir risk faktörüdür. Çalışmamızda 3-hidroksi-3 metilglutaril koenzim A redüktaz inhibitörlerinden olan Fluvastatin'in kombine hiperlipidemili hastalarda monoterapi olarak etkinliğini ve güvenilirliğini araştırmayı amaçladık. GEREÇ ve YÖNTEM: Kombine hiperlipidemi tespit edilen 83 hasta çalışmaya alındı. Birinci grupdaki 44 olguya diyet + 40mg/gün fluvastatin, ikinci grupdaki 35 olguya diyet + 80mg/gün fluvastatin ve üçüncü grupdaki 16 olguya ise diyet uygulandı. 28 hafta (4 hafta diyet+24 hafta ilaç) süren çalışma sırasında 6 hafta arayla, klinik ve laboratuar olarak 4 kontrol gerçekleştirildi. BULGULAR: Diyet grubu ile karşılaştırıldığında 40 mg ve 80 mg fluvastatin grubunda düşük dansiteli lipoprotein kolesterol (LDL-K) ve trigliserid (TG) düzeylerinin anlamlı olarak düştüğü saptanmıştır (40 mg grubunda sırasıyla p<0.001 ve p<0.01, 80 mg grubunda sırasıyla p<0.0001 ve p<0.000l). 40mg grubundan farklı olarak 80mg grubunda apolipoprotein B düzeylerinde anlamlı bir düşme (p<0.000l) ve yüksek dansiteli lipoprotein kolesterol (HDL-K) düzeylerinde de anlamlı bir artma (p<0.01) saptanmıştır. TG/LDL-K oranı 80 mg/gün grubunda diyet grubuna göre anlamlı olarak yüksekti (p<0.05). SONUÇ: Fluvastatin kombine hiperlipidemili hastalarda TG, LDL-K, ve apolipoprotein B konsantrasyonlarını düşürmüştür. HDL-K düzeylerinde ise diyetin ve egzersizin ilaç tedavisi kadar önemli olduğu gözükmektedir.

🔖

Cite This Article

TELLİ, H. H., TEMİZHAN, A., GÜRBİLEK, M., YAZICI, M. (2000). Kombine hiperlipidemili hastalarda tekbaşına fluvastatin tedavisi. MN Kardiyoloji, Cilt: 7 - Sayı: 6, 446–450. https://ajindex.com/articles/298107

References (1)

  1. Kannel WB, Thorn TJ. Incidence, prevalence and mortality of cardiovascular disease, in; Schland RC, Alexand er RW (eds) Hurst's the heart. 8 th ed. London. MC. Graw-Hill inc 1994; 185. Jones PH, Grundy SM, Gotto AM. The biochemistry of blood lipid regulation and the assesment of lipid abnormalities. In: Schland RC, Alexander RW, eds. Hurst's the heart. London: Me. Graw-Hill 1998;1553. Ross R. The Pathogoesis of Atherosclerosis, Dyslipidemia and other Risk Factors For Coronary Arter Disease and Acute Myocardiyal infarction. In: Braunwald E, eds. Heart Disease A Textbook of cardiovascular Medicine. Philadelphia: WB. Saunders Company 1997;1105. Christie M, Ballantyne MD, Herd JA, Ferlic LL, Dunn JK. Influence of low on Progresyon of Coronary Artery Disease and response to Fluvastatin Therapy. Circulation 1999:99:736. Andrews TC, Raby K, Barry J, Naimi CL. Effect of Cholesterol Reduction on Myocardial Ischemia in Patients With Coronary Disease. Circulation 1997;95;324. Grundy SM, Balady GJ, Criqui MH Fletcher G, Greenland P, Hiratzka LF ve ark. When to Start Cholesterol-lowering Therapy in Patients with Coronary Heart Disease. Circulation 1997;95:1683. Beil S, Pfafferott C.Weber M. fluvastatin Lipid-Lowering Effect in Routine Practice Conditions(FLIRT) Results of a Drug Surveillance Study. Clin. Drug investi 1997;14:146. Austin MA. Plasma triglyceride and coronary heart disease. Aterioscler Thromb 1991;11:2. NIH Consensus Development Panel on Triglyceride, High-Density Lipoprotein, and Coronary Heart Disease. Triglyceride, high-density lipoprotein, and coronary heart disease. JAMA 1993;269:505. Criqui MH, Heiss G, Cohn R, Cowan LD, Suchindran CM, Bangdiwala S, et al. Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med 1993;328:1220. Stein EA, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am J Cardiol 1998;4A:66B. Guerin M, Lassel TS, Le Goff W, Farnier M, Chapman MJ. Action of atorvastatin in combined hyperlipidemia; preferential reduction of cholesterol ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vase Biol 2000;20:189. Napoli C, Lepore S, Chiariello P, Condorelli M, Chiariello M. Long term treatment with Pravastatin alone and in combination with Gemfibrozil in familial type MB hyperlipoproteinemia or combined hyperlipidemia. J Cardiovasc Pharmacol Ther 1997;2:17. Stein EA, Davidson MH, Dujovne CA, Hunninghake DB, Goldberg RB, Illingworth DR, ve ark. Efficacy and tolerability of low-dos